Assertio (NASDAQ:ASRT) Posts Quarterly Earnings Results, Misses Expectations By $0.08 EPS

Assertio (NASDAQ:ASRT - Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.08), Zacks reports. The firm had revenue of $26.49 million for the quarter, compared to the consensus estimate of $27.52 million. Assertio had a negative net margin of 54.46% and a positive return on equity of 3.79%. During the same period last year, the company posted $0.04 earnings per share.

Assertio Stock Up 4.1%

Shares of ASRT traded up $0.03 on Friday, reaching $0.67. The stock had a trading volume of 341,077 shares, compared to its average volume of 684,113. The firm has a market capitalization of $63.77 million, a price-to-earnings ratio of -0.91, a price-to-earnings-growth ratio of 3.25 and a beta of 0.32. The company has a 50-day simple moving average of $0.65 and a 200-day simple moving average of $0.79. Assertio has a 12-month low of $0.51 and a 12-month high of $1.80. The company has a debt-to-equity ratio of 0.30, a quick ratio of 1.57 and a current ratio of 2.01.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. StockNews.com lowered Assertio from a "buy" rating to a "hold" rating in a research report on Monday, May 12th. Industrial Alliance Securities set a $1.75 target price on Assertio in a report on Friday, March 14th. HC Wainwright cut their price target on shares of Assertio from $4.00 to $3.50 and set a "buy" rating on the stock in a report on Wednesday, March 19th. Finally, Alliance Global Partners restated a "buy" rating on shares of Assertio in a report on Tuesday.

About Assertio

Assertio Holdings, Inc, a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis.